BridgeBio Pharma, Inc. (NASDAQ: BBIO) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $50.00 price target on the stock.
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 [Yahoo! Finance]
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024